SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Assembly Biosciences, Inc. (ASMB) News

Follow Assembly Biosciences, Inc. (ASMB) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 9 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol ASMB Asset equity Sector Markets 90 days 8 Last 22.22 Updated Nov 12, 2026, 09:02 PM UTC Open live news feed Open ASMB chart & news
M Assembly Biosciences Receives $75 Million Gilead Fee Assembly Biosciences received its first $75 million collaboration extension fee from Gilead and projects its cash runway into 2029. It also initiated a Phase 2 study of ABI-6250 and elected a 40% U.S. cost and profit sha EQUITY | Nov 12, 2026, 09:02 PM UTC M ASMB Q3'26 Earnings Preview: Revenue Estimate Assembly Biosciences is scheduled to report Q3'26 results on November 11. EPS is anticipated at $(0.66); the report time is unspecified. EQUITY | Nov 04, 2026, 12:01 PM UTC L Assembly Biosciences to present at H.C. Wainwright 28th Annual conference Assembly Biosciences, Inc. (NASDAQ:ASMB) said senior management will present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference. EQUITY | Sep 10, 2026, 08:21 PM UTC L Assembly Biosciences to present at H.C. Wainwright conference EQUITY | Sep 10, 2026, 08:15 PM UTC L Assembly Biosciences exercises profit-share option for herpes program Assembly Biosciences exercised a profit-sharing option under its collaboration with Gilead Sciences for a herpes treatment. It will share 40% of U.S. development costs and profits for the program. EQUITY | Sep 08, 2026, 08:49 PM UTC M ASMB exercises U.S. profit-share option with Gilead Assembly Biosciences (ASMB) exercised a U.S. profit-share option with Gilead for its HSV helicase-primase inhibitor program. EQUITY | Sep 08, 2026, 08:00 PM UTC L Mizuho cuts Assembly Biosciences price target to $45 Mizuho cut its price target on Assembly Biosciences to $45.00 per share from $53.00, according to Benzinga data. EQUITY | Sep 01, 2026, 02:59 PM UTC L UBS sets $52 price target for Assembly Biosciences UBS announced a $52.00/Share price target for Assembly Biosciences. EQUITY | Sep 01, 2026, 01:05 PM UTC L Assembly Biosciences reports Q2 2026 financial results and updates Assembly Biosciences (ASMB) reports its second quarter 2026 financial results and recent updates, according to TradeXchange Newsdesk. EARNINGS | Aug 13, 2026, 08:00 PM UTC